Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model-Reference-Cited by-同舟云学术

Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model

Published:2016-12-10 Issue:2 Volume:8 Page:3495-3508
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Dobson Christine C.¹²,Naing Thet¹,Beug Shawn T.¹,Faye Mame D.¹,Chabot Janelle¹,St-Jean Martin¹,Walker Danielle E.¹,LaCasse Eric C.¹,Stojdl David F.¹³,Korneluk Robert G.¹³,Holcik Martin¹⁴

Affiliation:

1. Molecular Biomedicine Program, Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada

2. Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada

3. Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada

4. Department of Pediatrics, University of Ottawa, Ottawa, ON, Canada

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells;Cell Biochemistry and Function;2024-06

2. Research Progress in the Use of Small Molecule Smac Mimetics in Combination Therapy of Cancer;Current Medicinal Chemistry;2024-05-20

3. The natural origins of cytostatic compounds used in rhabdomyosarcoma therapy;Advances in Clinical and Experimental Medicine;2023-03-15

4. Cellular resistance to an oncolytic virus is driven by chronic activation of innate immunity;iScience;2023-01

5. Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality;Frontiers in Immunology;2022-04-13